Evommune (EVMN) Asset Utilization Ratio (2025 - 2026)

Evommune's (EVMN) quarterly Asset Utilization Ratio came in at 0.05 in Q1 2026, down 43.46% on a QoQ basis from 0.08 in Q4 2025.

Evommune (EVMN) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Evommune (EVMN) has 2 years of Asset Utilization Ratio data on file, last reported at 0.05 in Q1 2026.

On a quarterly basis, Asset Utilization Ratio changed N/A year-over-year to 0.05 in Q1 2026; TTM through Mar 2026 was 0.05, a N/A change from a year earlier, with the FY2025 full-year figure at 0.09, changed N/A from the prior year.
Asset Utilization Ratio for Q1 2026 stood at 0.05, down from 0.08 in the prior quarter.
Over the last five years, Asset Utilization Ratio for EVMN reached as high as 0.08 in Q4 2025 and fell as low as 0.05 in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Evommune	381.48 Mn	170.02 Mn	-	0.05

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.05
Dec 31, 2025	0.08